dc.contributor.author | Constantinidou, Anastasia | en |
dc.contributor.author | Sebio, Ana | en |
dc.contributor.author | Benson, Charlotte | en |
dc.contributor.author | Antoniou, Georgios | en |
dc.contributor.author | Messiou, Christina | en |
dc.contributor.author | Miah, Aisha | en |
dc.contributor.author | Zaidi, Shane | en |
dc.contributor.author | Petruckevitch, Ann | en |
dc.contributor.author | Al-Muderis, Omar | en |
dc.contributor.author | Thway, Khin | en |
dc.contributor.author | VAN DER Graaf, Winette T. | en |
dc.contributor.author | Jones, Robin L. | en |
dc.creator | Constantinidou, Anastasia | en |
dc.creator | Sebio, Ana | en |
dc.creator | Benson, Charlotte | en |
dc.creator | Antoniou, Georgios | en |
dc.creator | Messiou, Christina | en |
dc.creator | Miah, Aisha | en |
dc.creator | Zaidi, Shane | en |
dc.creator | Petruckevitch, Ann | en |
dc.creator | Al-Muderis, Omar | en |
dc.creator | Thway, Khin | en |
dc.creator | VAN DER Graaf, Winette T. | en |
dc.creator | Jones, Robin L. | en |
dc.date.accessioned | 2021-02-23T14:38:17Z | |
dc.date.available | 2021-02-23T14:38:17Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 1791-7530 | |
dc.identifier.uri | http://gnosis.library.ucy.ac.cy/handle/7/64040 | |
dc.description.abstract | BACKGROUND/AIM: Treatment options for patients with metastatic soft tissue sarcomas are limited. Re-challenge with a previously successful gemcitabine-based regimen is common. There are no published data to support this practice. PATIENTS AND METHODS: We conducted a retrospective search to identify patients re-challenged with gemcitabine-based chemotherapy (GBC) from 2003 to 2015. RESULTS: Twenty-nine patients re-challenged with gemcitabine were identified. The response rate for initial GBC was 55% (n=15) and for re-challenge GBC 26% (n=6). The median progression-free survival was 11.1 months (95%CI=7.2-11.9) for initial GBC and 5.3 months (95%CI=2.0-7.5) for re-challenge GBC. Overall survival following gemcitabine re-challenge was 12.2 months (95%CI=7.0-18.2). Twelve out of 26 evaluable patients (46%) treated with re-challenge GBC experienced grade 3-4 adverse events (CTCAE 4.03) with 31% (n=8) of patients requiring dose reduction. CONCLUSION: In selected patients, gemcitabine re-challenge can be considered in advanced sarcomas, however, this approach is associated with toxicity. | en |
dc.language.iso | eng | en |
dc.source | Anticancer Research | en |
dc.source.uri | http://www.ncbi.nlm.nih.gov/pubmed/30591479 | |
dc.title | Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.21873/anticanres.13118 | |
dc.description.volume | 39 | |
dc.description.issue | 1 | |
dc.description.startingpage | 347 | |
dc.description.endingpage | 351 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.source.abbreviation | Anticancer Res. | en |
dc.contributor.orcid | Constantinidou, Anastasia [0000-0001-5316-7574] | |
dc.contributor.orcid | Messiou, Christina [0000-0002-0557-9379] | |
dc.gnosis.orcid | 0000-0001-5316-7574 | |
dc.gnosis.orcid | 0000-0002-0557-9379 | |